Lanthanum Orifarm (Lanthanum Carbonate)
Phosphate binder for hyperphosphatemia in chronic kidney disease
Quick Facts About Lanthanum Orifarm
Key Takeaways About Lanthanum Orifarm
- Must be chewed completely: Lanthanum Orifarm chewable tablets must never be swallowed whole to ensure proper phosphate binding in the stomach
- Take with meals: The tablets should be taken during or immediately after each meal to bind dietary phosphate effectively
- Minimal systemic absorption: Less than 0.002% of lanthanum is absorbed into the bloodstream, making it a locally acting treatment with few systemic side effects
- Regular monitoring required: Serum phosphate and calcium levels should be checked regularly to adjust the dose appropriately
- Separate from other medications: Take other oral medications at least 2 hours before or after Lanthanum Orifarm to avoid reduced absorption
What Is Lanthanum Orifarm and What Is It Used For?
Lanthanum Orifarm is a phosphate-binding medication containing lanthanum carbonate, used to control high blood phosphate levels (hyperphosphatemia) in adult patients with chronic kidney disease (CKD) who require dialysis. It works by binding to phosphate from food in the digestive tract, preventing it from entering the bloodstream.
When the kidneys function normally, they efficiently remove excess phosphate from the blood. However, in patients with end-stage renal disease (ESRD) or advanced chronic kidney disease, the kidneys can no longer adequately filter phosphate. This leads to a condition called hyperphosphatemia, where serum phosphate levels rise above the normal range of 0.81-1.45 mmol/L (2.5-4.5 mg/dL). If left untreated, elevated phosphate levels can cause serious and potentially life-threatening complications.
Hyperphosphatemia is a nearly universal complication of end-stage renal disease, affecting the vast majority of dialysis patients. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend maintaining serum phosphate levels toward the normal range in CKD patients on dialysis. Dietary phosphate restriction alone is usually insufficient to achieve this goal, making phosphate binders an essential part of treatment.
Lanthanum carbonate belongs to a class of medications called phosphate binders. Unlike older phosphate binders based on aluminium or calcium, lanthanum carbonate is a rare earth element that provides effective phosphate binding without the risks associated with aluminium toxicity or calcium overload. It has a high affinity for phosphate and works across a wide pH range in the gastrointestinal tract, from the acidic environment of the stomach to the more alkaline conditions of the small intestine.
How does Lanthanum Orifarm work?
The mechanism of action of lanthanum carbonate is straightforward and occurs entirely within the gastrointestinal tract. When the chewable tablet is taken with food and chewed thoroughly, lanthanum ions (La3+) are released in the acidic environment of the stomach. These lanthanum ions then bind to dietary phosphate to form highly insoluble lanthanum phosphate complexes. These complexes cannot be absorbed through the intestinal wall and are instead excreted in the feces, effectively reducing the amount of phosphate that enters the bloodstream.
One of the key advantages of lanthanum carbonate is its extremely low systemic absorption. Studies have shown that less than 0.002% of the administered dose is absorbed into the bloodstream. This means that lanthanum acts almost entirely as a local agent within the gut, minimizing the risk of systemic side effects. The small amount that is absorbed is primarily eliminated through the bile into the feces, with negligible renal excretion.
Why is phosphate control important?
Uncontrolled hyperphosphatemia in CKD patients can lead to several serious complications. Elevated phosphate stimulates the parathyroid glands to produce excess parathyroid hormone (PTH), leading to secondary hyperparathyroidism. This condition causes increased bone resorption, resulting in a bone disorder known as renal osteodystrophy, which increases the risk of fractures, bone pain, and deformities.
Perhaps most critically, high phosphate levels promote vascular calcification, where calcium-phosphate crystals are deposited in blood vessel walls and heart valves. This process significantly increases cardiovascular risk, and cardiovascular disease is the leading cause of death in dialysis patients. Studies published in the New England Journal of Medicine and Kidney International have consistently demonstrated that higher serum phosphate levels are independently associated with increased mortality in CKD patients.
Phosphate is found naturally in protein-rich foods such as meat, fish, dairy products, and eggs. It is also widely used as a food additive (often listed as E338-E343 or E450-E452) in processed foods, soft drinks, and baked goods. Patients on dialysis are typically advised to follow a phosphate-restricted diet alongside taking phosphate binders like Lanthanum Orifarm.
What Should You Know Before Taking Lanthanum Orifarm?
Before taking Lanthanum Orifarm, inform your doctor if you have inflammatory bowel disease (Crohn's disease or ulcerative colitis), bowel obstruction, peptic ulcer disease, or liver problems. The medication is not recommended during pregnancy or breastfeeding. Always tell your doctor about all other medications you are taking.
While Lanthanum Orifarm is generally well tolerated due to its minimal systemic absorption, there are several important considerations before starting treatment. Your prescribing physician will assess your individual medical history and determine whether lanthanum carbonate is appropriate for your situation. Proper patient selection and awareness of potential risks are essential for safe and effective use.
Contraindications
Lanthanum Orifarm should not be taken in the following circumstances:
- Hypersensitivity: If you are allergic to lanthanum carbonate or any of the other ingredients in the tablet
- Hypophosphatemia: If your blood phosphate levels are already below normal, as further phosphate reduction could be dangerous
Your doctor will check your serum phosphate levels before prescribing Lanthanum Orifarm and at regular intervals during treatment. Treatment should only be initiated when serum phosphate exceeds the target range recommended by current KDIGO guidelines.
Warnings and Precautions
Special caution is required in certain patient populations. Discuss the following conditions with your doctor before starting treatment:
- Inflammatory bowel disease: Patients with Crohn's disease, ulcerative colitis, or other inflammatory gastrointestinal conditions should use Lanthanum Orifarm with caution, as there is limited clinical experience in these populations. The local gastrointestinal action of the medication may theoretically exacerbate mucosal inflammation
- Bowel obstruction or ileus: Lanthanum Orifarm should not be used in patients with active bowel obstruction, as it could worsen the condition. If symptoms of obstruction develop during treatment (severe abdominal pain, bloating, absent bowel movements), seek immediate medical attention
- Peptic ulcer disease: Patients with active peptic ulcers should be treated with caution due to the potential for local irritation
- Hepatic impairment: Although lanthanum undergoes minimal systemic absorption, the small fraction that is absorbed is eliminated via the bile. Patients with significant liver disease may have altered biliary excretion, and careful monitoring is advised
- Peritonitis: In patients on peritoneal dialysis, episodes of peritonitis should be managed according to standard protocols. The experience with lanthanum carbonate in peritoneal dialysis patients with peritonitis is limited
Lanthanum Orifarm tablets must be chewed thoroughly before swallowing. Do not swallow the tablets whole. Swallowing whole tablets may reduce the effectiveness of the medication and could potentially cause gastrointestinal complications. If you have difficulty chewing, discuss alternative phosphate binder options with your doctor.
Pregnancy and Breastfeeding
Lanthanum Orifarm is not recommended during pregnancy. Although systemic absorption is extremely low, there are insufficient clinical data on the use of lanthanum carbonate in pregnant women. Animal reproductive studies have shown some adverse effects at high doses. Women of childbearing potential should use effective contraception during treatment.
It is not known whether lanthanum or its metabolites are excreted in human breast milk. Due to the potential for unknown risks to the nursing infant, a decision should be made whether to discontinue breastfeeding or to discontinue lanthanum carbonate, taking into account the importance of the drug to the mother. Given that most women on dialysis have reduced fertility, this consideration arises less frequently in clinical practice, but it remains an important discussion point.
If you become pregnant while taking Lanthanum Orifarm, contact your doctor immediately. They will assess whether to continue treatment or switch to an alternative phosphate binder with a more established safety profile in pregnancy.
Children and adolescents
Lanthanum Orifarm is not recommended for use in children and adolescents under 18 years of age. Clinical trials have not established the safety and efficacy of lanthanum carbonate in pediatric CKD patients. The potential effects of lanthanum on developing bones and other organ systems in growing children have not been adequately studied. Pediatric patients with hyperphosphatemia should be managed with alternative phosphate binders that have established pediatric safety data.
How Does Lanthanum Orifarm Interact with Other Drugs?
Lanthanum Orifarm can reduce the absorption of certain medications when taken at the same time. Tetracycline and fluoroquinolone antibiotics, levothyroxine, oral bisphosphonates, and some other medications should be taken at least 2 hours before or after Lanthanum Orifarm. It does not significantly interact with warfarin, digoxin, or common antihypertensives.
As a divalent/trivalent cation, lanthanum has the potential to form insoluble complexes with certain drugs in the gastrointestinal tract, similar to other phosphate binders. This can reduce the bioavailability of co-administered medications. The clinical significance of these interactions depends on the specific drug involved and its therapeutic window. Understanding these interactions is crucial for patients on dialysis, who typically take multiple medications concurrently.
The European Medicines Agency (EMA) and regulatory authorities worldwide have evaluated the interaction profile of lanthanum carbonate through both in vitro and clinical pharmacokinetic studies. The results provide practical guidance for timing the administration of co-medications.
| Medication | Interaction Type | Severity | Recommended Action |
|---|---|---|---|
| Tetracycline antibiotics (doxycycline, minocycline) | Reduced absorption of tetracycline | Major | Take tetracycline at least 2 hours before or after lanthanum |
| Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) | Reduced absorption of fluoroquinolone | Major | Take fluoroquinolone at least 2 hours before or after lanthanum |
| Levothyroxine | Reduced absorption of levothyroxine | Major | Take levothyroxine at least 2 hours before lanthanum; monitor TSH |
| Oral bisphosphonates (alendronate) | Reduced absorption of bisphosphonate | Moderate | Separate administration by at least 2 hours |
| Mycophenolate mofetil | Potential reduced absorption | Moderate | Monitor immunosuppressant levels; consider separating doses |
| Warfarin | No clinically significant interaction | Low | No dose adjustment needed; monitor INR per standard practice |
| Digoxin | No clinically significant interaction | Low | No dose adjustment needed |
Major Interactions
The most clinically significant interactions involve medications that are known to form chelation complexes with polyvalent cations. Tetracycline antibiotics and fluoroquinolone antibiotics are particularly susceptible to reduced absorption when co-administered with lanthanum carbonate. Clinical studies have shown that the bioavailability of ciprofloxacin can be reduced by approximately 50% when taken simultaneously with lanthanum, which could lead to therapeutic failure in treating infections.
Levothyroxine (thyroid hormone replacement) is another medication that requires careful separation. Patients with hypothyroidism who are also taking lanthanum carbonate should take their levothyroxine at least 2 hours before the phosphate binder, preferably on an empty stomach in the morning. Thyroid function tests (TSH) should be monitored more frequently when initiating or adjusting lanthanum therapy in patients on levothyroxine.
Minor Interactions
Clinical pharmacokinetic studies have demonstrated that lanthanum carbonate does not significantly affect the absorption or blood levels of several commonly used medications in dialysis patients. These include:
- Warfarin: No clinically meaningful change in INR or warfarin pharmacokinetics
- Digoxin: No significant alteration in digoxin levels
- Metoprolol: No effect on beta-blocker absorption
- Enalapril: No effect on ACE inhibitor bioavailability
Nevertheless, as a general precaution, it is advisable to take any oral medication for which a reduction in bioavailability could have a clinically significant effect at least 2 hours before or after Lanthanum Orifarm. This is particularly important for medications with a narrow therapeutic index. Always inform your healthcare provider and pharmacist about all medications, supplements, and herbal products you are taking.
Since Lanthanum Orifarm is taken with meals, a practical approach is to take most other medications either first thing in the morning (before breakfast) or at bedtime, when you are not eating. Your pharmacist or dialysis nurse can help you create a medication schedule that minimizes interaction risks while ensuring all doses are taken correctly.
What Is the Correct Dosage of Lanthanum Orifarm?
The usual starting dose of Lanthanum Orifarm is 750 mg to 1500 mg per day, divided across meals (e.g., one 500 mg tablet with each meal). The dose is adjusted every 2-3 weeks based on serum phosphate levels, up to a maximum of 3000 mg per day. Tablets must be chewed completely before swallowing.
The dosage of Lanthanum Orifarm is individualized based on the patient's serum phosphate levels and clinical response. Your doctor will determine the most appropriate starting dose and adjust it over time to achieve and maintain target phosphate levels. The goal of treatment is to bring serum phosphate into the range recommended by current KDIGO guidelines (typically 1.13-1.78 mmol/L or 3.5-5.5 mg/dL for dialysis patients).
Adults
Standard adult dosage
Starting dose: 750 mg to 1500 mg per day, divided across the main meals of the day. The most common initial regimen is one 500 mg chewable tablet taken with each of the three main meals (breakfast, lunch, and dinner), totaling 1500 mg per day.
Dose titration: The dose should be titrated every 2-3 weeks until acceptable serum phosphate levels are reached. Typical increments are 750 mg per day (adding one additional 500 mg tablet to one of the meals).
Maintenance dose: Most patients require between 1500 mg and 3000 mg per day, divided across meals.
Maximum dose: 3000 mg per day (6 tablets of 500 mg). Some clinical situations may warrant higher doses under close medical supervision.
| Patient Group | Starting Dose | Maintenance Dose | Maximum Dose |
|---|---|---|---|
| Adults (hemodialysis) | 1500 mg/day (3 x 500 mg) | 1500-3000 mg/day | 3000 mg/day |
| Adults (peritoneal dialysis) | 1500 mg/day (3 x 500 mg) | 1500-3000 mg/day | 3000 mg/day |
| Elderly (≥65 years) | 750-1500 mg/day | Titrate based on response | 3000 mg/day |
| Children (<18 years) | Not recommended - insufficient safety data | ||
Children
Lanthanum Orifarm is not recommended for children and adolescents under 18 years of age. The safety and efficacy of lanthanum carbonate have not been established in the pediatric population. Pediatric patients with hyperphosphatemia should be managed with alternative phosphate binders such as calcium-based binders or sevelamer, which have more extensive pediatric safety data. If you are caring for a child with chronic kidney disease, consult a pediatric nephrologist for appropriate phosphate management strategies.
Elderly
No specific dose adjustment is generally required for elderly patients aged 65 years and over. However, given the higher likelihood of concomitant medical conditions and polypharmacy in elderly patients, it may be prudent to start with a lower initial dose of 750 mg per day and titrate gradually. Elderly patients should be monitored closely for gastrointestinal side effects, nutritional status, and serum phosphate and calcium levels. Clinical trials included patients up to 80 years of age, and no significant differences in safety or efficacy were observed between older and younger adults.
Missed Dose
If you forget to take a dose of Lanthanum Orifarm with a meal, skip the missed dose and take your next scheduled dose with your next meal. Do not take a double dose to make up for the forgotten one. Since the medication works by binding phosphate in food, taking it between meals (when there is no dietary phosphate to bind) provides no benefit. If you frequently forget doses, consider using a pill organizer or setting medication reminders to help you stay on schedule.
Overdose
There is limited clinical experience with overdose of lanthanum carbonate. Given the very low systemic absorption of lanthanum (<0.002%), acute overdose is unlikely to cause systemic toxicity. The expected symptoms of an overdose would primarily be gastrointestinal in nature, including nausea, vomiting, and abdominal discomfort. Additionally, an overdose could lead to excessively low serum phosphate levels (hypophosphatemia), which can cause muscle weakness, confusion, and cardiac arrhythmias.
If you suspect an overdose, contact your local poison control center or emergency department. Treatment is supportive and symptomatic. Serum phosphate and calcium levels should be monitored, and phosphate supplementation may be necessary if significant hypophosphatemia develops.
What Are the Side Effects of Lanthanum Orifarm?
The most common side effects of Lanthanum Orifarm are gastrointestinal symptoms including nausea (affecting more than 1 in 10 patients), vomiting, diarrhea, abdominal pain, constipation, and flatulence. These effects are usually mild to moderate and often improve over the first weeks of treatment. Serious side effects are rare.
Like all medicines, Lanthanum Orifarm can cause side effects, although not everybody gets them. Because the medication acts locally in the gastrointestinal tract with minimal systemic absorption, the vast majority of side effects are related to the digestive system. Clinical trials and post-marketing surveillance data from the European Medicines Agency (EMA) provide comprehensive information about the frequency and nature of adverse effects.
Most gastrointestinal side effects occur during the first few weeks of treatment and tend to diminish as the body adjusts to the medication. If side effects are bothersome or persistent, discuss them with your doctor, who may adjust the dose or suggest strategies to manage symptoms. Do not stop taking Lanthanum Orifarm without consulting your healthcare provider, as uncontrolled phosphate levels can lead to serious complications.
Very Common
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Common
- Constipation
- Flatulence (gas)
- Dyspepsia (indigestion)
- Abdominal distension (bloating)
- Hypocalcemia (low calcium levels)
- Headache
Uncommon
- Hypophosphatemia (excessively low phosphate levels)
- Gastroesophageal reflux
- Stomatitis (mouth inflammation)
- Tooth disorder
- Changes in taste
- Fatigue
- Dizziness
Rare
- Gastrointestinal obstruction
- Subileus (partial bowel obstruction)
- Eosinophilic gastrointestinal disorders
- Allergic reactions (hypersensitivity)
- Increased blood aluminium levels (in patients with concurrent aluminium exposure)
Long-term safety data from clinical trials lasting up to 6 years have been reassuring. Unlike aluminium-based phosphate binders, lanthanum carbonate has not been associated with aluminium-related neurotoxicity or aluminium bone disease. Unlike calcium-based phosphate binders, it does not contribute to hypercalcemia or vascular calcification. These advantages are important considerations for the long-term management of hyperphosphatemia in dialysis patients.
Most gastrointestinal side effects are mild and improve with time. However, contact your healthcare provider if you experience severe or persistent abdominal pain, inability to pass gas or stools (which could indicate bowel obstruction), blood in your stools, or signs of an allergic reaction such as rash, swelling of the face or throat, or difficulty breathing. Also report any unexplained muscle weakness or confusion, which could indicate hypophosphatemia.
How Should You Store Lanthanum Orifarm?
Store Lanthanum Orifarm at room temperature below 25°C (77°F) in the original packaging to protect from moisture. Keep out of reach and sight of children. Do not use after the expiry date printed on the packaging.
Proper storage of medication is essential to ensure it remains effective and safe throughout its shelf life. Lanthanum Orifarm chewable tablets should be stored according to the following guidelines:
- Temperature: Store at or below 25°C (77°F). Do not refrigerate or freeze the tablets
- Moisture protection: Keep the tablets in the original blister packaging or container until you are ready to take them. Lanthanum carbonate can absorb moisture from the air, which may affect the texture and chewability of the tablets
- Light protection: No special light protection is required, but storing in the original packaging is recommended
- Children: Keep the medicine out of reach and sight of children at all times. Use child-resistant packaging where available
Check the expiry date on the packaging before each use. Do not use Lanthanum Orifarm after the expiry date (EXP) printed on the blister or container. The expiry date refers to the last day of that month. Expired medication should be returned to your pharmacy for safe disposal. Do not dispose of medications via household waste or wastewater, as this can contribute to environmental contamination.
If you notice any change in the appearance, color, or texture of the tablets (such as crumbling, discoloration, or unusual odor), do not use them. Contact your pharmacist for advice and a replacement supply. Patients who travel should take care to protect their medication from extreme temperatures, particularly during air travel where cargo hold temperatures can be very low.
What Does Lanthanum Orifarm Contain?
Each Lanthanum Orifarm 500 mg chewable tablet contains lanthanum carbonate hydrate equivalent to 500 mg of lanthanum (as the active ingredient). Excipients include dextrates (hydrated), colloidal anhydrous silica, magnesium stearate, and talc.
Understanding the complete composition of your medication is important, particularly if you have known allergies or intolerances to specific excipients. The following is a breakdown of the components of Lanthanum Orifarm chewable tablets:
Active ingredient
The active substance is lanthanum carbonate hydrate. Each chewable tablet contains lanthanum carbonate hydrate equivalent to 500 mg of lanthanum. Lanthanum is a rare earth element (atomic number 57) that has been selected for its high phosphate-binding capacity and favorable safety profile. The carbonate salt form provides stability and allows the release of lanthanum ions in the gastric acidic environment.
Inactive ingredients (excipients)
The excipients in Lanthanum Orifarm 500 mg chewable tablets serve various pharmaceutical purposes:
- Dextrates (hydrated): A sweetening and bulking agent that provides the tablet mass and helps achieve a pleasant taste for chewing
- Colloidal anhydrous silica: A flow agent used during manufacturing to ensure uniform tablet content
- Magnesium stearate: A lubricant that prevents the tablet material from sticking to manufacturing equipment. Note: the amount of magnesium from this excipient is negligible and does not contribute clinically to magnesium intake
- Talc: A glidant used to improve powder flow during tablet compression
The tablets do not contain lactose, gluten, or artificial colors. However, patients with severe allergies should always check the full excipient list on the patient information leaflet supplied with the medication and discuss any concerns with their pharmacist or doctor.
Lanthanum is a naturally occurring rare earth element. Despite its classification as a "rare earth," it is actually relatively abundant in the Earth's crust. In pharmaceutical use, it has been studied extensively for over two decades and has an established safety profile. The extremely low systemic absorption (<0.002%) means that the body is exposed to only trace amounts of lanthanum during treatment.
Frequently Asked Questions About Lanthanum Orifarm
Medical References and Sources
This article is based on current medical research and international guidelines. All claims are supported by scientific evidence from peer-reviewed sources.
- European Medicines Agency (EMA). "Summary of Product Characteristics: Lanthanum carbonate." Last updated 2024. Regulatory assessment and approved prescribing information for the European market.
- KDIGO CKD-MBD Work Group (2024). "KDIGO 2024 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)." Kidney International Supplements. International guidelines for managing phosphate levels in CKD patients. Evidence level: 1A
- Daugirdas JT, et al. (2020). "Handbook of Dialysis." 5th Edition. Wolters Kluwer. Comprehensive reference for dialysis management including phosphate binder use.
- Hutchison AJ, et al. (2008). "Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study." Nephron Clinical Practice. 110(1):c15-23. Key long-term safety and efficacy study for lanthanum carbonate.
- Malluche HH, et al. (2008). "Two-year cortical and cancellous bone histology in patients treated with lanthanum carbonate." Clinical Journal of the American Society of Nephrology. 3(6):1798-805. Bone biopsy study demonstrating safety of long-term lanthanum use on bone health.
- Navaneethan SD, et al. (2011). "Phosphate binders for preventing and treating bone disease in chronic kidney disease patients." Cochrane Database of Systematic Reviews. Systematic review comparing efficacy of different phosphate binders. Evidence level: 1A
- Block GA, et al. (2004). "Mineral metabolism, mortality, and morbidity in maintenance hemodialysis." Journal of the American Society of Nephrology. 15(8):2208-2218. Landmark study linking serum phosphate levels to mortality in dialysis patients.
- U.S. Food and Drug Administration (FDA). "Fosrenol (lanthanum carbonate) Prescribing Information." Last updated 2023. FDA-approved labeling with comprehensive safety and efficacy data.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in nephrology, pharmacology, internal medicine, and general practice.